Moreover, Mui et al. [94] reported that SGLT2 inhibitor users had a lower incidence of dementia than DPP-4 inhibitor users in a retrospective cohort study of patients with diabetes using SGLT2 or DPP-4 inhibitors from 1 January 2015 to 31 December 2019. This evidence concerns the gene SLC5A2 and dementia.